Glycopeptide-intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected U.S. hospitals

Journal of Clinical Microbiology

Volumn 37, Issue 11, 1999, Pages 3590-3593

  Hubert, Susannah K ^a   Mohammed, Jasmine M ^b   Fridkin, Scott K ^b   Gaynes, Robert P ^b   McGowan Jr , John E ^a,c   Tenover, Fred C ^b  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; COST EFFECTIVENESS ANALYSIS; HEALTH SURVEY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SCREENING TEST; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 0032884728     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.11.3590-3593.1999     Document Type: Article

References (18)

1. Bannerman, T. L., G. Hancock, F. C. Tenover, and J. M. Miller. 1995. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J. Clin. Microbiol. 33:551-555.
2. Centers for Disease Control and Prevention. 1997. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. Morbid. Mortal. Weekly Rep. 46:624-628.
3. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:765-766.
4. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid Mortal. Weekly Rep. 46:813-815.
5. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
6. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
7. Howe, R. A., K. E. Bowker, T. R. Walsh, T. G. Feest, and A. P. MacGowan. 1998. Vancomycin-resistant Staphylococcus aureus. Lancet 351:602.
8. Kloos, W. E., and T. L. Bannerman. 1995. Staphylococcus and Micrococcus, p. 282-298. In P. R. Murray, E. J. Barron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
9. Monnet, D. L., L. K. Archibald, L. Phillips, F. C. Tenover, J. E. McGowan, Jr., R. P. Gaynes, the Intensive Care Antimicrobial Resistance Epidemiology Project, and the National Nosocomial Infections Surveillance Systems Hospitals. 1998. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Infect. Control Hosp. Epidemiol. 19:388-394.
10. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., vol. 17, no. 2. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests, 6th ed., vol. 17, no. 1. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing - 8th informational supplement, vol. 18, no. 1. Document M100-S8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Ploy, M. C., C. Grélaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
14. Rotun, S. S., V. McMath, D. J. Schoonmaker, P. S. Maupin, F. C. Tenover, B. C. Hill, and D. A. Ackman. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. J. 5:147-149.
15. Sieradzki, K., P. Villari, and A. Tomasz. 1998. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 42:100-107.
16. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
17. Tenover, F. C., M. Lancaster, B. Hill, C. Steward, S. Stocker, G. Hancock, C. O'Hara, N. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
18. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.